Abstract
Introduction Nearly all patients with primary ciliary dyskinesia (PCD) report ear-nose-throat (ENT) symptoms. However, scarce evidence exists about how ENT symptoms relate to pulmonary disease in PCD. We explored possible associations between upper and lower respiratory disease among patients with PCD in a multicentre study.
Methods We included patients from the ENT Prospective International Cohort (EPIC-PCD). We studied associations of several reported ENT symptoms and chronic rhinosinusitis (CRS)—defined using patient-reported information and examination findings—with reported sputum production and shortness of breath—using ordinal logistic regression. In a subgroup with available lung function results, we used linear regression to study associations of CRS and FEV1, accounting for relevant factors.
Results We included 457 patients [median age: 15; interquartile range (IQR) 10–24; 54% males]. Shortness of breath associated with reported nasal symptoms and ear pain of any frequency, often or daily hearing problems, headache when bending down [odds ratio (OR) 2.1; 95% confidence interval (CI) 1.29–3.54], and CRS (OR 2.3; 95% CI 1.57–3.38) regardless of polyp presence. Sputum production associated with daily reported nasal (OR 2.2; 95% CI 1.20–4.09) and hearing (OR 2.0; 95% CI 1.10–3.64) problems and CRS (OR 2.1; 95% CI 1.48–3.07). We did not find any association between CRS and FEV1.
Conclusion Reported upper airway symptoms and signs of CRS associated with reported pulmonary symptoms; however, not with lung function. Our results emphasise assessing and managing upper and lower respiratory disease as a common, interdependent entity among patients with PCD.
Competing Interest Statement
Authors participate in the BEAT-PCD (Better experimental approaches to treat PCD) clinical research collaboration-supported by the European Respiratory Society-and most centres are members of the PCD core of ERN-LUNG (European Reference Network on rare respiratory diseases). JF Papon reports personal fees from Sanofi, GSK, Medtronic, and ALK outside submitted work. M Alexandru received personal fees from Sanofi and ALK outside of submitted work. M Boon reports grants from Forton grant (King Baudouin Foundation) 2020-J1810150-217926 cystic fibrosis research and personal fees from Vertex outside submitted work. N Lorent received honoraria to her institution from GSK, INSMED, AN2 Therapeutics outside submitted work and a travel grant from Pfizer. J Roehmel received grants, clinical study recompensations from Vertex, INSMED, and Medical Research Council/UK, BMBF, Mukoviszidose Institut outside of submitted work.
Funding Statement
The Swiss National Science Foundation Ambizione fellowship (PZ00P3_185923) funded the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been reviewed and approved by the local Human Research Ethics Committees at every participating centre, based on local legislation. We list below the names of the ethics committees which approved the study and the approval reference numbers, when applicable. A. The following centres have a pre-existing or new ethical approval, which allows the contribution of pseudonymised data to observational collaborative international studies (covers the EPIC-PCD study): 1. University Childrens Hospital Charite-Universitaetsmedizin, Berlin, Germany: Ethical Committee Charite (EA2/003/21) 2. University Childrens hospital, Bern, Switzerland: Cantonal Ethics Committee of Bern (KEKBE: 060/2015) 3. University of Cyprus: Ethical Committee for biomedical research in Leukosia Cyprus (EEBK/EΠ/2013/21) 4. Marmara University Istanbul, Turkey: Ethical Committee of Marmara University (09.2018.395) 5. University Hospital of Southampton, United Kingdom: Southampton and South West Hampshire research ethics committee (06/Q1702/109) 6. University hospital Muenster, Germany: Ethical committee (2011-270-f-S) B. The following centres applied for ethical approval to participate specifically to the EPIC-PCD study: 1. VU University medical center (VUmc), Amsterdam, The Netherlands: The Medical Ethics Review Committee of VU University Medical Center reviewed the application and concluded on 24th of November 2020 that no approval is needed to participate to the EPIC-PCD cohort as the Medical Research Involving Human Subjects Act does not apply to the study. 2. Hacettepe University, Ankara, Turkey: Non-interventional clinical research EC of Hacettepe University (2020/11-47) 3. University Hospital of Leuven, Belgium: Ethical Committee for Research of University Hospitals Leuven (S64411) 4. Hospital Universitario La Fe in Valencia, Spain: Ethical Committee of medical investigations of Hospital Universitario La Fe (2020-498-1) 5. University Hospital Bicetre Paris-Sud, Paris, France: The AP-HP Direction de la Recherche Clinique et de l'Innovation reviewed the application and concluded on 4th of February 2021 that that no approval is needed to participate to the EPIC-PCD cohort as the Jarde law that regulates clinical research in France does not apply to the study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Group co-authorship: a list of all names can be found at the end of the manuscript
Message Upper and lower airway disease occurs interdependently for patients with PCD and needs assessed as a common entity with appropriate clinical and patient-reported measures and managed accordingly to improve clinical outcomes.
Availability of data and materials
Upon reasonable request, our datasets for the present study are available from the study PI, Dr. Myrofora Goutaki (myrofora.goutaki{at}unibe.ch). The EPIC - PCD dataset includes individual patient data of people with a rare disease. Although data are pseudonymised, data possibly still include sensitive information which possibly lead to identifying participants; therefore, participants were not asked to consent having their data deposited or shared publicly.
